Stevo Najman1,2, Mike Barbeck3,4, Ole Jung5, Milena Radenkovic6, Sanja Stojanović6, Caroline Lindner7, Milijana Batinic4, Oliver Görke4, Jens Pissarek8, Annica Pröhl7. 1. Department of Biology and Human Genetics, Faculty of Medicine, University of Niš, Niš, Serbia. 2. Department for Cell and Tissue Engineering, Scientific Research Center for Biomedicine, Faculty of Medicine, University of Niš, Niš, Serbia. 3. BerlinAnalytix GmbH, Berlin, Germany mike.barbeck@berlinanalytix.com. 4. Department of Ceramic Materials, Chair of Advanced Ceramic Materials, Institute for Materials Science and Technologies, Technical University Berlin, Berlin, Germany. 5. Clinic and Policlinic for Dermatology and Venereology, University Medical Center Rostock, Rostock, Germany. 6. Department for Cell and Tissue Engineering, Faculty of Medicine, University of Niš, Niš, Serbia. 7. BerlinAnalytix GmbH, Berlin, Germany. 8. Biotrics bioimplants GmbH, Berlin, Germany.
Abstract
BACKGROUND/AIM: For the treatment of different tissue defects such as jawbone defects, open wound defect, chronic ulcers, dura mater defects and corneal defects, different biomaterials are available. The use of collagen-based materials for these applications has been significantly increased over the past decades due to its excellent biocompatibility and degradability. However, no transparent collagen-based biomaterial is available until now. Thus, a newly developed transparent collagen membrane (TCM) based on natural derived porcine pericardium, which offers numerous application possibilities, was developed. The present study aimed to analyze the in vitro and in vivo biocompatibility using established methods. MATERIALS AND METHODS: The new TCM membrane and a commercially available collagen membrane (CM, Jason membrane, botiss biomaterials GmbH, Zossen, Germany) were tested for its in vitro cytocompatibility. Furthermore, the in vivo biocompatibility was analyzed using sham operations as control group. In vitro, cytocompatibility was tested in accordance with EN ISO 10993-5/-12 regulations and Live-Dead-stainings. In vivo, a subcutaneous implantation model in BALB/c mice was used and explants were prepared for analyses by established histological, immunohistochemical and histomorphometrical methods. RESULTS: In vitro, both membranes showed promising cytocompatibility with a slightly better direct cell response in the Live-Dead staining assay for the TCM. In vivo, TCM induced a comparable inflammatory immune response after 10 and 30 days with comparable numbers of M1- and M2-macrophages as also found in the control group without biomaterial insertion. CONCLUSION: The newly transparent collagen membrane is fully biocompatible and is supporting safe clinical application in tissue repair and surgery. Copyright
BACKGROUND/AIM: For the treatment of different tissue defects such as jawbone defects, open wound defect, chronic ulcers, dura mater defects and corneal defects, different biomaterials are available. The use of collagen-based materials for these applications has been significantly increased over the past decades due to its excellent biocompatibility and degradability. However, no transparent collagen-based biomaterial is available until now. Thus, a newly developed transparent collagen membrane (TCM) based on natural derived porcine pericardium, which offers numerous application possibilities, was developed. The present study aimed to analyze the in vitro and in vivo biocompatibility using established methods. MATERIALS AND METHODS: The new TCM membrane and a commercially available collagen membrane (CM, Jason membrane, botiss biomaterials GmbH, Zossen, Germany) were tested for its in vitro cytocompatibility. Furthermore, the in vivo biocompatibility was analyzed using sham operations as control group. In vitro, cytocompatibility was tested in accordance with EN ISO 10993-5/-12 regulations and Live-Dead-stainings. In vivo, a subcutaneous implantation model in BALB/c mice was used and explants were prepared for analyses by established histological, immunohistochemical and histomorphometrical methods. RESULTS: In vitro, both membranes showed promising cytocompatibility with a slightly better direct cell response in the Live-Dead staining assay for the TCM. In vivo, TCM induced a comparable inflammatory immune response after 10 and 30 days with comparable numbers of M1- and M2-macrophages as also found in the control group without biomaterial insertion. CONCLUSION: The newly transparent collagen membrane is fully biocompatible and is supporting safe clinical application in tissue repair and surgery. Copyright
Authors: Maria G Patino; Mirdza E Neiders; Sebastiano Andreana; Bernice Noble; Robert E Cohen Journal: J Oral Implantol Date: 2002 Impact factor: 1.779
Authors: Daniel Rothamel; Frank Schwarz; Anton Sculean; Monika Herten; Werner Scherbaum; Jürgen Becker Journal: Clin Oral Implants Res Date: 2004-08 Impact factor: 5.977
Authors: Ole Jung; Ralf Smeets; Dario Porchetta; Alexander Kopp; Christoph Ptock; Ute Müller; Max Heiland; Max Schwade; Björn Behr; Nadja Kröger; Lan Kluwe; Henning Hanken; Philip Hartjen Journal: Acta Biomater Date: 2015-06-11 Impact factor: 8.947
Authors: Alexander Florian Elsaesser; Christian Bermueller; Silke Schwarz; Ludwig Koerber; Roman Breiter; Nicole Rotter Journal: Tissue Eng Part A Date: 2014-02-06 Impact factor: 3.845
Authors: M Barbeck; S E Udeabor; J Lorenz; A Kubesch; J Choukroun; R A Sader; C J Kirkpatrick; S Ghanaati Journal: Ann Maxillofac Surg Date: 2014 Jul-Dec
Authors: Ole Jung; Ralf Smeets; Philip Hartjen; Reinhard Schnettler; Frank Feyerabend; Martin Klein; Nils Wegner; Frank Walther; Dominic Stangier; Anders Henningsen; Carsten Rendenbach; Max Heiland; Mike Barbeck; Alexander Kopp Journal: Int J Mol Sci Date: 2019-01-10 Impact factor: 5.923
Authors: Sven Pantermehl; Said Alkildani; Elisa Meyer; Ignacio Stowe; Jens Pissarek; Pia Moosmann; Ole Jung; Mike Barbeck Journal: In Vivo Date: 2022 Jan-Feb Impact factor: 2.155
Authors: Ole Jung; Mike Barbeck; L U Fan; Fabian Korte; Cuifeng Zhao; Rumen Krastev; Sven Pantermehl; Xin Xiong Journal: In Vivo Date: 2021 Sep-Oct Impact factor: 2.406